News

PharmiWeb4h
Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study
CARDIFF, UNITED KINGDOM / ACCESS Newswire / June 18, 2025 / When it comes to type 1 diabetes, treating this chronic condition ...
Biodexa Pharmaceuticals: Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study
CARDIFF, UNITED KINGDOM / ACCESS Newswire / June 18, 2025 / When it comes to type 1 diabetes, treating this chronic condition can be difficult. After all, with this type of diabetes, the body's immune ...
Eli Lilly Buys Verve Therapeutics: Aims To Permanently Lower Your Cholesterol
Eli Lilly (LLY) will acquire Verve Therapeutics (VERV) for up to $13.5/share, aiming to revolutionize cholesterol treatment.
Zacks Investment Research on MSN2h
Here's Why Novo Nordisk (NVO) is a Strong Momentum Stock
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
Verywell Health on MSN20h
Don't Ditch Seed Oils—New Study Suggests They're Actually Good for You
New research suggests that the omega-6 fatty acids in seed oils may actually help lower inflammation, contrary to social ...
The Lancet16h
Re-evaluating the concept of remission in type 2 diabetes: a call for patient-centric approaches
Controlling weight and cardiovascular risk factors is paramount in type 2 diabetes management; however, the definition and feasibility of remission warrant closer examination. Type 2 diabetes ...